Cheshire-based Alexion Pharmaceuticals Inc. said today it has filed an application to begin treating Japanese patients with its patented drug to counter a rare disorder that destroys red blood cells.
Alexion’s new drug application in Japan seeks clearance for commercial use of the Soliris blood disorder treatment on Japanese patients, beginning in 2010.
Soliris already has U.S., Australian, Canadian and European approval as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis.
At 11 a.m., Alexion traded at $36.02, down $1.64, or 4.4 percent.
